Follow
Friedrich Stölzel
Friedrich Stölzel
University Hospital Schleswig-Holstein
Verified email at uksh.de
Title
Cited by
Cited by
Year
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ...
Leukemia 29 (10), 2062-2068, 2015
5842015
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
F Kroschinsky, F Stölzel, S von Bonin, G Beutel, M Kochanek, M Kiehl, ...
Critical Care 21, 1-11, 2017
4152017
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ...
Bone marrow transplantation 43 (3), 245-251, 2009
3842009
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting …
C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, ...
Journal of clinical oncology 29 (20), 2758-2765, 2011
3142011
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 …
U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ...
The Lancet Oncology 19 (12), 1668-1679, 2018
2802018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ...
Nature medicine 24 (3), 282-291, 2018
2502018
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
C Röllig, C Thiede, M Gramatzki, W Aulitzky, H Bodenstein, M Bornhäuser, ...
Blood, The Journal of the American Society of Hematology 116 (6), 971-978, 2010
2282010
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, ...
Nature medicine 23 (1), 69-78, 2017
2222017
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
M Noviello, F Manfredi, E Ruggiero, T Perini, G Oliveira, F Cortesi, ...
Nature communications 10 (1), 1065, 2019
1342019
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
F Stölzel, C Röllig, J Radke, B Mohr, U Platzbecker, M Bornhäuser, ...
Haematologica 96 (10), 1552, 2011
1252011
Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome
F von Dalowski, M Kramer, M Wermke, R Wehner, C Röllig, N Alakel, ...
Stem Cells 34 (2), 357-366, 2016
1182016
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or …
DW Beelen, R Trenschel, M Stelljes, C Groth, T Masszi, P Reményi, ...
The Lancet Haematology 7 (1), e28-e39, 2020
1092020
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis
T Herold, KH Metzeler, S Vosberg, L Hartmann, C Röllig, F Stölzel, ...
Blood, The Journal of the American Society of Hematology 124 (8), 1304-1311, 2014
1072014
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, ...
Blood advances 4 (20), 5011-5024, 2020
1052020
Karyotype complexity and prognosis in acute myeloid leukemia
F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, WE Berdel, ...
Blood cancer journal 6 (1), e386-e386, 2016
992016
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
C Röllig, M Kramer, C Schliemann, JH Mikesch, B Steffen, A Krämer, ...
Blood, The Journal of the American Society of Hematology 136 (7), 823-830, 2020
962020
TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
JM Middeke, S Herold, E Rücker‐Braun, WE Berdel, M Stelljes, ...
British journal of haematology 172 (6), 914-922, 2016
932016
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ...
Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022
892022
Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts
L Angenendt, C Röllig, P Montesinos, D Martínez-Cuadrón, E Barragan, ...
Journal of Clinical Oncology 37 (29), 2632, 2019
882019
Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia
T Bochtler, F Stölzel, CE Heilig, C Kunz, B Mohr, A Jauch, JWG Janssen, ...
Journal of clinical oncology 31 (31), 3898-3905, 2013
812013
The system can't perform the operation now. Try again later.
Articles 1–20